REG - Haleon PLC - Transaction in Own Shares

HALEONAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250512:nRSL1581Ia&default-theme=true

RNS Number : 1581I  Haleon PLC  12 May 2025

 Haleon plc: Transaction in own shares

 12 May 2025: Haleon plc (the "Company" or "Haleon") today announces the
 purchase of the following number of ordinary shares of £0.01 each in the
 Company (the "Shares") for cancellation under its share buyback programme
 announced on 28 March 2025 (the "Buyback Programme").

 Date of purchase:                                  09 May 2025
 Number of Shares purchased:                        830,397
 Highest price paid per share (p):                  407.00
 Lowest price paid per share (p):                   402.70
 Volume weighted average price paid per share (p):  405.03

Date of purchase:                                  09 May 2025
 Number of Shares purchased:                        830,397
 Highest price paid per share (p):                  407.00
 Lowest price paid per share (p):                   402.70
 Volume weighted average price paid per share (p):  405.03

 Following the settlement of the above, the Company's registered share capital
 is 9,016,724,418 ordinary shares of £0.01 each, of which 4,080,205 are held
 as treasury shares. Therefore, the number of ordinary shares with voting
 rights is 9,012,644,213 and this figure may be used by shareholders to
 determine if they are required to notify their interest, or a change to their
 interest, in Haleon under the FCA's Disclosure Guidance and Transparency
 Rules.

 In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it
 applies in the UK

 (the Market Abuse Regulation), a full breakdown of the individual trades is
 available at the link below:

 http://www.rns-pdf.londonstockexchange.com/rns/1581I_1-2025-5-9.pdf
 (http://www.rns-pdf.londonstockexchange.com/rns/1581I_1-2025-5-9.pdf)

 This announcement does not constitute, or form part of, an offer or any
 solicitation of an offer for securities in any jurisdiction.

 This announcement and individual trade breakdown will also be available on the
 Company's website at: www.haleon.com/investors
 (http://www.haleon.com/investors) .

 Enquiries

 Investors                      Media
 Jo Russell    +44 7787 392441  Zoë Bird         +44 7736 746167
 Rakesh Patel  +44 7552 484646  Victoria Durman  +44 7894 505730
 Emma White    +44 7823 523562
 Email: investor-relations@haleon.com    Email: corporate.media@haleon.com

Email: corporate.media@haleon.com

 About Haleon

 Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose
 to deliver better everyday health with humanity. Haleon's product portfolio
 spans six major categories - Oral Health, Vitamins, Minerals and Supplements
 (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin
 Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin,
 Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on
 trusted science, innovation and deep human understanding.

 For more information, please visit www.haleon.com.

 

 Haleon plc: Transaction in own shares

 12 May 2025: Haleon plc (the "Company" or "Haleon") today announces the
 purchase of the following number of ordinary shares of £0.01 each in the
 Company (the "Shares") for cancellation under its share buyback programme
 announced on 28 March 2025 (the "Buyback Programme").

 Date of purchase:                                  09 May 2025
 Number of Shares purchased:                        830,397
 Highest price paid per share (p):                  407.00
 Lowest price paid per share (p):                   402.70
 Volume weighted average price paid per share (p):  405.03

Date of purchase:                                  09 May 2025
 Number of Shares purchased:                        830,397
 Highest price paid per share (p):                  407.00
 Lowest price paid per share (p):                   402.70
 Volume weighted average price paid per share (p):  405.03

 

 Following the settlement of the above, the Company's registered share capital
 is 9,016,724,418 ordinary shares of £0.01 each, of which 4,080,205 are held
 as treasury shares. Therefore, the number of ordinary shares with voting
 rights is 9,012,644,213 and this figure may be used by shareholders to
 determine if they are required to notify their interest, or a change to their
 interest, in Haleon under the FCA's Disclosure Guidance and Transparency
 Rules.

 In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it
 applies in the UK

 (the Market Abuse Regulation), a full breakdown of the individual trades is
 available at the link below:

 http://www.rns-pdf.londonstockexchange.com/rns/1581I_1-2025-5-9.pdf
 (http://www.rns-pdf.londonstockexchange.com/rns/1581I_1-2025-5-9.pdf)

 This announcement does not constitute, or form part of, an offer or any
 solicitation of an offer for securities in any jurisdiction.

 This announcement and individual trade breakdown will also be available on the
 Company's website at: www.haleon.com/investors
 (http://www.haleon.com/investors) .

 Enquiries

Investors                      Media
 Jo Russell    +44 7787 392441  Zoë Bird         +44 7736 746167
 Rakesh Patel  +44 7552 484646  Victoria Durman  +44 7894 505730
 Emma White    +44 7823 523562

 Email: investor-relations@haleon.com    Email: corporate.media@haleon.com

Email: corporate.media@haleon.com

 About Haleon

 Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose
 to deliver better everyday health with humanity. Haleon's product portfolio
 spans six major categories - Oral Health, Vitamins, Minerals and Supplements
 (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin
 Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin,
 Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on
 trusted science, innovation and deep human understanding.

 For more information, please visit www.haleon.com.

 Haleon plc: Transaction in own shares

 12 May 2025: Haleon plc (the "Company" or "Haleon") today announces the
 purchase of the following number of ordinary shares of £0.01 each in the
 Company (the "Shares") for cancellation under its share buyback programme
 announced on 28 March 2025 (the "Buyback Programme").

 Date of purchase:                                  09 May 2025
 Number of Shares purchased:                        830,397
 Highest price paid per share (p):                  407.00
 Lowest price paid per share (p):                   402.70
 Volume weighted average price paid per share (p):  405.03

 Date of purchase:                                  09 May 2025
 Number of Shares purchased:                        830,397
 Highest price paid per share (p):                  407.00
 Lowest price paid per share (p):                   402.70
 Volume weighted average price paid per share (p):  405.03

 Following the settlement of the above, the Company's registered share capital
 is 9,016,724,418 ordinary shares of £0.01 each, of which 4,080,205 are held
 as treasury shares. Therefore, the number of ordinary shares with voting
 rights is 9,012,644,213 and this figure may be used by shareholders to
 determine if they are required to notify their interest, or a change to their
 interest, in Haleon under the FCA's Disclosure Guidance and Transparency
 Rules.

 In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it
 applies in the UK

 (the Market Abuse Regulation), a full breakdown of the individual trades is
 available at the link below:

 http://www.rns-pdf.londonstockexchange.com/rns/1581I_1-2025-5-9.pdf
 (http://www.rns-pdf.londonstockexchange.com/rns/1581I_1-2025-5-9.pdf)

 This announcement does not constitute, or form part of, an offer or any
 solicitation of an offer for securities in any jurisdiction.

 This announcement and individual trade breakdown will also be available on the
 Company's website at: www.haleon.com/investors
 (http://www.haleon.com/investors) .

 Enquiries

 Investors                      Media
 Jo Russell    +44 7787 392441  Zoë Bird         +44 7736 746167
 Rakesh Patel  +44 7552 484646  Victoria Durman  +44 7894 505730
 Emma White    +44 7823 523562

 Email: investor-relations@haleon.com    Email: corporate.media@haleon.com

 Email: corporate.media@haleon.com

 About Haleon

 Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose
 to deliver better everyday health with humanity. Haleon's product portfolio
 spans six major categories - Oral Health, Vitamins, Minerals and Supplements
 (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin
 Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin,
 Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on
 trusted science, innovation and deep human understanding.

 For more information, please visit www.haleon.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  POSDKLFBEELXBBV